Allergan Brought Into Widening U.S. Probe of Generic Drug Prices

Updated on

Allergan Plc’s Actavis unit got a subpoena from the U.S. Justice Department seeking information on the marketing and prices of its generic drugs, becoming the biggest company yet to draw scrutiny in the government’s widening antitrust probe of the industry.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.